Login
Toggle sidebar

Lint: papillary-craniopharyngioma

papillary-craniopharyngioma
Strong List Colon Position
error

"T1: 85% are T1 hypointense 4"

Line 58:8 · When enboldening an intro, the colon should not be bold. '<strong>T1:</strong> 85'

"T1: iso- to slightly hypointense to brain"

Line 64:8 · When enboldening an intro, the colon should not be bold. '<strong>T1:</strong> iso'

"T1 C+ (Gd): vivid enhancement"

Line 65:8 · When enboldening an intro, the colon should not be bold. '<strong>T1 C+ (Gd):</strong> vivid'

"T2: variable/mixed"

Line 66:8 · When enboldening an intro, the colon should not be bold. '<strong>T2:</strong> variable'

"MR spectroscopy: cyst contents does not show a broad lipid spectrum as they are filled with aqueous fluid"

Line 69:8 · When enboldening an intro, the colon should not be bold. '<strong>MR spectroscopy:</strong> cyst'
Emphasis
warning

"Molecular evidence has, demonstrated that the vast majority (>90%) papillary craniopharyngiomas have distinct mutations of BRAF and these are a useful in separating them from adamantinomatous craniopharyngiomas that have CTNNB1 mutations, with only rare coexistence of BRAF mutations 1-3,10,11."

Line 26:127 · Italics should be used only in exceptional circumstances: '<em>BRAF</em>'
Acronyms
warning

"Furthermore, as the vast majority of papillary craniopharyngiomas tumours have BRAF V600E mutations, treatment with BRAF-MEK inhibition (e.g. combination vemurafenib-cobimetinib or dabrafenib-trametinib) has been tried in patients with residual disease following surgery with positive early results 8."

Line 74:129 · 'BRAF-MEK' has no definition. Spell it out if it's unfamiliar to the audience.
Links
0
0
0
0
64
6
0
0
0
2
1
7
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0